La Jolla Pharmaceutical (NASDAQ:LJPC) COO Jennifer Carver purchased 1,000 shares of the company’s stock in a transaction that occurred on Thursday, December 27th. The shares were bought at an average cost of $33.22 per share, with a total value of $33,220.00. Following the transaction, the chief operating officer now directly owns 4,500 shares of the company’s stock, valued at approximately $149,490. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Jennifer Carver also recently made the following trade(s):

  • On Wednesday, December 27th, Jennifer Carver purchased 1,000 shares of La Jolla Pharmaceutical stock. The shares were bought at an average cost of $33.22 per share, with a total value of $33,220.00.

Shares of La Jolla Pharmaceutical (NASDAQ LJPC) opened at $32.18 on Tuesday. La Jolla Pharmaceutical has a 52 week low of $16.71 and a 52 week high of $39.28. The stock has a market cap of $718.61, a P/E ratio of -6.31 and a beta of 1.62.

La Jolla Pharmaceutical (NASDAQ:LJPC) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported ($1.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.24) by $0.05. analysts expect that La Jolla Pharmaceutical will post -4.91 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Legal & General Group Plc grew its stake in La Jolla Pharmaceutical by 11.6% during the second quarter. Legal & General Group Plc now owns 4,456 shares of the biopharmaceutical company’s stock worth $133,000 after buying an additional 462 shares during the period. Nationwide Fund Advisors grew its stake in La Jolla Pharmaceutical by 20.4% during the second quarter. Nationwide Fund Advisors now owns 9,952 shares of the biopharmaceutical company’s stock worth $296,000 after buying an additional 1,688 shares during the period. The Manufacturers Life Insurance Company grew its stake in La Jolla Pharmaceutical by 19.2% during the second quarter. The Manufacturers Life Insurance Company now owns 13,397 shares of the biopharmaceutical company’s stock worth $399,000 after buying an additional 2,162 shares during the period. Wells Fargo & Company MN grew its stake in La Jolla Pharmaceutical by 23.0% during the second quarter. Wells Fargo & Company MN now owns 16,937 shares of the biopharmaceutical company’s stock worth $504,000 after buying an additional 3,167 shares during the period. Finally, New York State Common Retirement Fund grew its stake in La Jolla Pharmaceutical by 21.2% during the second quarter. New York State Common Retirement Fund now owns 18,300 shares of the biopharmaceutical company’s stock worth $545,000 after buying an additional 3,199 shares during the period.

Several brokerages recently commented on LJPC. Zacks Investment Research lowered shares of La Jolla Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Tuesday, October 10th. Jefferies Group reaffirmed a “buy” rating and set a $40.00 price target on shares of La Jolla Pharmaceutical in a research report on Tuesday, October 3rd. ValuEngine raised shares of La Jolla Pharmaceutical from a “strong sell” rating to a “sell” rating in a research report on Tuesday, December 26th. BidaskClub raised shares of La Jolla Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Wednesday, December 27th. Finally, SunTrust Banks set a $65.00 price target on shares of La Jolla Pharmaceutical and gave the stock a “buy” rating in a research report on Thursday, December 28th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $57.14.

TRADEMARK VIOLATION NOTICE: This article was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://www.thecerbatgem.com/2018/01/02/la-jolla-pharmaceutical-ljpc-coo-jennifer-carver-purchases-1000-shares.html.

La Jolla Pharmaceutical Company Profile

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH).

Receive News & Stock Ratings for La Jolla Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical and related stocks with our FREE daily email newsletter.